zilurgisertib   Click here for help

GtoPdb Ligand ID: 11888

Synonyms: Compound A [WO2021257532A1] | example 34 [US20210155606A1]
Compound class: Synthetic organic
Comment: The chemical structure for zilurgisertib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a serine/threonine kinase inhibitor. It is one of the compounds that are claimed in Novartis' ALK2 (ACVR1) inhibitor patent US20210155606A1 [1], and it is also claimed in WO2021257532A1 by Incyte as "Compound A" [2]. Incyte have declared an ALK2 inhibitor (INCB00928) in their development pipeline, but the name-to-structure has not been formally disclosed.

ALK2/ACVR1 is a serine/threonine protein kinase receptor for type I bone morphogenic protein (BMP), and this signalling pathway is crucial in bone formation, and hyperactivty of the pathway is associated with diseases that are characterised by bone malformation, such as fibrodysplasia ossificans progressiva (FOP). ALK2 is also involved in the maintenance of iron homeostasis by governing production of the iron regulatory hormone hepcidin. Elevated hepcidin is thought to be a powerful driver of the pathophysiology of anemia that's associated with chronic disease. Inhibition of ALK2 upstream of hepcidin should increase circulating iron levels. Thus direct inhibition of ALK2/ACVR1 is a molecular mechanism that is being expolited for therapeutic potential in FOP and anemia arising from chronic kidney disease or myeloproliferative diseases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 100.71
Molecular weight 502.29
XLogP 3.62
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1cc(cnc1N)c1ccc(cc1)[C@@]12CN(C[C@H]2C1)C1CCOCC1)NC12CCC(CC1)(CC2)O
Isomeric SMILES Nc1ncc(cc1C(=O)NC12CCC(CC1)(CC2)O)c1ccc(cc1)[C@]12CN(C[C@H]1C2)C1CCOCC1
InChI InChI=1S/C30H38N4O3/c31-26-25(27(35)33-28-7-10-29(36,11-8-28)12-9-28)15-21(17-32-26)20-1-3-22(4-2-20)30-16-23(30)18-34(19-30)24-5-13-37-14-6-24/h1-4,15,17,23-24,36H,5-14,16,18-19H2,(H2,31,32)(H,33,35)/t23-,28?,29?,30+/m1/s1
Bioactivity Comments
Retains activity against the AKL2 R206H mutant that is associated with fibrodysplasia ossificans progressiva [1].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
activin A receptor type 1 Hs Inhibitor Inhibition 7.6 pIC50 - 1
pIC50 7.6 (IC50 2.3x10-8 M) [1]
activin A receptor type IL Hs Inhibitor Inhibition 6.5 pIC50 - 1
pIC50 6.5 (IC50 3.23x10-7 M) [1]
bone morphogenetic protein receptor type IA Hs Inhibitor Inhibition 6.0 pIC50 - 1
pIC50 6.0 (IC50 9.14x10-7 M) [1]
bone morphogenetic protein receptor type IB Hs Inhibitor Inhibition 5.5 pIC50 - 1
pIC50 5.5 (IC50 3.3x10-6 M) [1]
transforming growth factor beta receptor 1 Hs Inhibitor Inhibition 5.2 pIC50 - 1
pIC50 5.2 (IC50 6.28x10-6 M) [1]